Ганетеспиб

Ganetespib, also known as STA-9090, is a unique resorcinolic triazolone inhibitor of Hsp90, which is currently in clinical trials for a number of human cancers. It has shown promise in preclinical tests against various cancers, including lung cancer, prostate cancer, and leukemia. Moreover, It has also shown strong activity toward breast cancer, non-small cell lung cancer, gastric cancer, and acute myeloid leukemia.

ChEBI: Ganetespib is a member of triazoles and a ring assembly. It is a synthetic small-molecule inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic activity.

Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in In Vitro and In Vivo Models of Non–Small Cell Lung Cancer DOI:10.1158/1078-0432.CCR-11-2967
https://www.cancer.gov/publications/dictionaries/cancer-drug/def/ganetespib
Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy DOI: 10.1158/1535-7163.MCT-11-0755
Role of Ganetespib, an HSP90 Inhibitor, in Cancer Therapy: From Molecular Mechanisms to Clinical Practice doi: 10.3390/ijms24055014
A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies DOI:10.1186/1471-2407-13-152
Ganetespib synergizes with cyclophosphamide to improve survival of mice with autochthonous tumors in a mutant p53-dependent manner DOI:10.1038/cddis.2017.108